Erik Goluboff, MD, MBA, Tyra Biosciences, Inc.

Affiliations:

Tyra Biosciences, Inc.

Carlsbad, CA, USA

Articles by Erik Goluboff, MD, MBA, Tyra Biosciences, Inc.

Oral Selective FGFR3 Inhibition in Urothelial Carcinoma: Opportunities in Intermediate Risk Non-Muscle Invasive Bladder Cancer and Low Grade Upper Tract Urothelial Carcinoma

ByErik Goluboff, MD, MBA, Tyra Biosciences, Inc.

March 30th 2026

Latest Updated Articles

Trending on Urology Times

Active surveillance use for low-risk prostate cancer reaches 93% in VA System

FDA receives NDA submission for UGN-103 in recurrent LG-IR-NMIBC

Focal therapy for prostate cancer frequently used outside guideline-supported groups

HoLEP learning curve and strategies for successful adoption, with Daniel S. Kellner, MD

Ryan Flannigan, MD, highlights phase 2 data on ST-01 for chronic scrotal content pain